UA74968C2 - Amlodipine bezylate tablets with improved stability and process for their preparation - Google Patents
Amlodipine bezylate tablets with improved stability and process for their preparation Download PDFInfo
- Publication number
- UA74968C2 UA74968C2 UA20040705877A UA20040705877A UA74968C2 UA 74968 C2 UA74968 C2 UA 74968C2 UA 20040705877 A UA20040705877 A UA 20040705877A UA 20040705877 A UA20040705877 A UA 20040705877A UA 74968 C2 UA74968 C2 UA 74968C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tablets
- amlodipine
- active ingredient
- tablet
- mass
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 14
- 229960000528 amlodipine Drugs 0.000 title abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 6
- 229960004005 amlodipine besylate Drugs 0.000 claims description 31
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 20
- 238000003825 pressing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105345A HU226642B1 (en) | 2001-12-17 | 2001-12-17 | Amlodipine bezylate tablets having extended stability and process for producing the same |
| PCT/HU2002/000145 WO2003051364A1 (en) | 2001-12-17 | 2002-12-17 | Amlopidine bezylate tablets with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74968C2 true UA74968C2 (en) | 2006-02-15 |
Family
ID=90000366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705877A UA74968C2 (en) | 2001-12-17 | 2002-12-17 | Amlodipine bezylate tablets with improved stability and process for their preparation |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1458384B1 (es) |
| AT (1) | ATE333877T1 (es) |
| AU (1) | AU2002353242A1 (es) |
| BG (1) | BG108807A (es) |
| CZ (1) | CZ2004791A3 (es) |
| DE (1) | DE60213464T2 (es) |
| EA (1) | EA006826B1 (es) |
| ES (1) | ES2269787T3 (es) |
| HR (1) | HRP20040582B1 (es) |
| HU (1) | HU226642B1 (es) |
| LT (1) | LT5241B (es) |
| LV (1) | LV13243B (es) |
| PL (1) | PL370420A1 (es) |
| RS (1) | RS54304A (es) |
| SK (1) | SK2862004A3 (es) |
| UA (1) | UA74968C2 (es) |
| WO (1) | WO2003051364A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| JP4954961B2 (ja) * | 2008-10-06 | 2012-06-20 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| JP5689052B2 (ja) * | 2011-12-26 | 2015-03-25 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| WO2013121233A1 (en) | 2012-02-17 | 2013-08-22 | Egis Gyógyszergyár Nyilvánosan Működö Részvénytársaság | Pharmaceutical formulation having improved stability |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE19857716A1 (de) * | 1998-12-15 | 2000-06-21 | Bayer Ag | Neue feste Formulierung von Metrifonat |
| WO2003032954A1 (en) * | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
-
2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
-
2002
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 EP EP02788262A patent/EP1458384B1/en not_active Expired - Lifetime
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/en active IP Right Grant
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
-
2004
- 2004-06-23 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002353242A1 (en) | 2003-06-30 |
| HUP0105345A3 (en) | 2007-08-28 |
| DE60213464T2 (de) | 2007-03-01 |
| ES2269787T3 (es) | 2007-04-01 |
| LT2004062A (en) | 2005-02-25 |
| DE60213464D1 (de) | 2006-09-07 |
| HRP20040582A2 (en) | 2005-02-28 |
| EP1458384B1 (en) | 2006-07-26 |
| HUP0105345D0 (en) | 2002-02-28 |
| LV13243B (en) | 2005-05-20 |
| CZ2004791A3 (cs) | 2004-10-13 |
| PL370420A1 (en) | 2005-05-30 |
| LT5241B (lt) | 2005-07-25 |
| BG108807A (en) | 2005-03-31 |
| EA006826B1 (ru) | 2006-04-28 |
| HUP0105345A2 (hu) | 2003-12-29 |
| WO2003051364A1 (en) | 2003-06-26 |
| HRP20040582B1 (en) | 2007-08-31 |
| SK2862004A3 (en) | 2004-11-03 |
| RS54304A (en) | 2006-12-15 |
| ATE333877T1 (de) | 2006-08-15 |
| EP1458384A1 (en) | 2004-09-22 |
| EA200400801A1 (ru) | 2004-12-30 |
| HU226642B1 (en) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gohel et al. | Preparation and assessment of novel coprocessed superdisintegrant consisting of crospovidone and sodium starch glycolate: a technical note | |
| KR20120078751A (ko) | 발사르탄 및 암로디핀의 고체 투여 형태 및 이의 제조 방법 | |
| JP2008543767A5 (es) | ||
| MX2012000892A (es) | Formas de dosificacion de citrato ferrico. | |
| EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| US5087454A (en) | Ibuprofen tablet | |
| JPWO2018230504A1 (ja) | 顆粒剤、並びに錠剤及びその製造方法 | |
| UA74968C2 (en) | Amlodipine bezylate tablets with improved stability and process for their preparation | |
| JP2009513530A5 (es) | ||
| Aljaberi et al. | Tableting functionality evaluation of Prosolv Easytab in comparison to physical mixtures of its individual components | |
| WO2008020990A1 (en) | New direct compressible excipient blend | |
| JP2004521890A (ja) | 非吸湿性バルプロ酸ナトリウム組成物の製造方法 | |
| JP5644167B2 (ja) | 溶出改善されたケトチフェン又はその塩を含有する固形製剤 | |
| GB2444904A (en) | A process for the preparation of an orally administered unit dose tablet | |
| CZ290911B6 (cs) | Stabilní prostředky obsahující levosimendan a kyselinu alginovou | |
| SINGH et al. | Effect of ZEIN on ciprofloxacin floating tablets | |
| Vinoth Kumar et al. | Formulation and evaluation of orodispersible liquisolid compacts of nifedipine using co-processed superdisintegrants | |
| JP6037687B2 (ja) | グリメピリドを含有する口腔内崩壊錠 | |
| AU632376B2 (en) | Pressing not delayed release of active compound, process for its production and use of polyhydroxybutyric acid for the production of such a pressing | |
| Kushare et al. | Design and Development of a Microwave Generated Lactose Monohydrate-Microcrystalline Cellulose Based Multifunctional Excipient Composites for Tablet Formulation using Box–Behnken Design | |
| Mohammed et al. | Effects of a co-processed novel multifunctional excipient on the tablet properties of metronidazole | |
| EP2692342A1 (en) | Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets | |
| Asker et al. | Effect of scaling-up and formulation factors on the qualities of prednisone tablets | |
| JPH0291018A (ja) | 湿気に対して安定な固形バルプロ酸製剤とその製造法 | |
| Karthikeyan et al. | Formulation And Evaluation Of Zolpidem Tartrate Extended Release Matrix Tablets |